Clinical trials: GLP - 1
glp1 Agonist, Gene Expression
Ellacor® Micro-Coring Technology® in Fitzpatrick Skin Types I-VI, Including Patients Receiving Glucagon-Like Peptide-1 Receptor Agonists
The main purpose of the study is to collect information about how the device functions in a variety of treatment areas and skin types and to find out what changes, if any, occur in the skin treated with the study device compared…
- Conditions
- glp1 Agonist, Gene Expression, Skin Laxity
- Trial name
- NCT07224880
- Testing
- ellacor
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Cytrellis Biosystems, Inc.
Type 2 Diabetes Mellitus
A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone
The goal for this study is to evaluate the efficacy and safety of tirzepatide versus placebo in participants with type 2 diabetes not under control with diet and exercise alone.
- Trial name
- SURPASS-1 (NCT03954834)
- Testing
- Tirzepatide
- Where
- 53 sites in United States, India and 3 more
- Volunteers
- 478 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes
To Evaluate Efficacy and Safety of HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus
This is a randomized, double-blind, placebo controlled, parallel group study, which aims to provide data on efficacy, safety and pharmacokinetics (PK) of multiple dose levels of HDM1002 tablets in adults with type 2 diabetes…
- Trial name
- NCT06481085
- Testing
- HDM1002 50 mg, HDM1002 100 mg, HDM1002 200 mg
- Where
- 31 sites in China
- Volunteers
- 324 people
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Type2diabetes
Comparison of the Safety, Efficacy and Pharmacokinetics of DehydraTECH -CBD and DehydraTECH-GLP1 Agonists Alone or in Combination, in Overweight or Obese, Pre- and Type 2 Diabetic Participants
This is a Phase 1b, randomized, open-label, active-controlled, parallel, multiple-dose study comparing the safety, pharmacokinetics and efficacy of DehydraTECH Cannabidiol and Glucagon-like Peptide 1 (GLP-1) agonists alone and in…
- Trial name
- DehydraTECH (NCT06648031)
- Testing
- Arm 1 - DehydraTECH-CBD alone, Arm 2 - DehydraTECH-semaglutide alone, Arm 3 - DehydraTECH-CBD in combination with DehydraTECH-semaglutide
- Where
- 7 sites in Australia
- Volunteers
- 148 people
- Sponsor
- Lexaria Bioscience Corp.
Weight Management
A Phase 3 Study to Evaluate the Efficacy of XW003 in Adults With Overweight or Obesity
The aim of the study is to evaluate the efficacy and safety of XW003 versus placebo in adults with overweight or obesity
- Trial name
- NCT05813795
- Testing
- Ecnoglutide Low Dosage, Ecnoglutide Medium Dosage, Ecnoglutide High Dosage
- Where
- China
- Volunteers
- 664 people
- Sponsor
- Hangzhou Sciwind Biosciences Co., Ltd.
Type 2 Diabetes
Exenatide Plus Pioglitazone Versus Insulin in Poorly Controlled T2DM
To compare efficacy, safety and durability of combination therapy with pioglitazone plus GLP-1 RA versus basal bolus insulin in poorly controlled T2DM patients on metformin plus sulfonylurea
- Trial name
- NCT02887625
- Testing
- Pioglitazone plus exenatide, insulin glargine and insulin aspart
- Where
- Qatar
- Volunteers
- 410 people
- Sponsor
- Dr. Muhammad Abdulghani
Healthy
A Drug-Drug Interaction (DDI) Study of Orforglipron With Carbamazepine in Healthy Participants
The main purpose of this study is to assess the effect of carbamazepine on the amount of orforglipron in the bloodstream and how long it takes the body to get rid of orforglipron when given orally in healthy study participants.
- Trial name
- NCT06370728
- Testing
- Orforglipron, Carbamazepine
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes Mellitus
A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes
The purpose of the trial is to assess the efficacy and safety of tirzepatide to dulaglutide in participants with type 2 diabetes and increased cardiovascular risk.
- Trial name
- SURPASS-CVOT (NCT04255433)
- Testing
- Tirzepatide, Dulaglutide
- Where
- 635 sites in United States, Argentina and 29 more
- Volunteers
- 13,299 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes Mellitus
Effectiveness and Safety of Treatment of Insulin Glargine in Type 2 Diabetes Mellitus Following Glucagon-like Peptide-1 (GLP-1) Failure
Primary Objective: To assess the efficacy of insulin glargine as measured by changes of HbA1c levels from baseline in type 2 diabetes mellitus (T2DM) patients following GLP-1 failure.
- Trial name
- GAUDI (NCT01461577)
- Testing
- INSULIN GLARGINE HOE 901
- Where
- Japan
- Volunteers
- 89 people
- Sponsor
- Sanofi
Non-alcoholic Steatohepatitis
A Thorough QTC Study to Assess the Effect of Cotadutide on Cardiac Repolarization in Healthy Participants
This study will investigate the effect of multiple doses of cotadutide on the cardiac activity (QTc interval) of healthy participants.
- Trial name
- NCT05668936
- Testing
- Cotadutide, Moxifloxacin
- Where
- Germany
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2, Diabetes Melletus
A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan Fasting
The purpose of this study is to test the efficacy and safety of orforglipron in participants with T2D (type 2 diabetes) who participate in fasting during Ramadan.
- Conditions
- Diabetes Mellitus, Type 2, Diabetes Melletus, Glucose Metabolism Disorders, Metabolic Disorders
- Trial name
- ACHIEVE-RAM (NCT07613307)
- Testing
- Orforglipron
- Where
- 40 sites in India, Saudi Arabia and 2 more
- Volunteers
- 130 people
- Sponsor
- Eli Lilly and Company
Overweight or Obesity
Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes
This study will test an experimental drug called olatorepatide ("study drug") to determine how safe and effective this drug is compared to placebo and how easily the body can accept this drug at different doses and dosing…
- Trial name
- NCT07685808
- Testing
- Olatorepatide
- Where
- 21 sites in United States
- Volunteers
- 360 people
- Sponsor
- Regeneron Pharmaceuticals
Healthy Adult Subject, Overweight Subject
A Drug-Drug Interaction (DDI) Study of HDM1002 With Repaglinide, Atorvastatin, Digoxin and Rosuvastatin in Healthy Subjects and Overweight Subjects.
The purpose of this study is to characterize the effect of HDM1002 on the PK of single dose of repaglinide, atorvastatin, digoxin and rosuvastatin in healthy adult subjects.
- Trial name
- NCT06601517
- Testing
- Repaglinide, Atorvastatin, Digoxin
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Obesity
A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity
The main purpose of this study is to determine if combining tirzepatide with mibavademab will result in more weight loss in adult participants than tirzepatide alone.
- Trial name
- NCT06373146
- Testing
- Tirzepatide, Mibavademab
- Where
- 17 sites in United States
- Volunteers
- 392 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes (T2D)
iGlarLixi CGM Study in Chinese T2D Individuals After OADs
This study is an open-label, 1:1 randomized, active-controlled, 2-arm, 20-week treatment duration, parallel-group, multicenter, phase IV study to evaluate the effect of iGlarLixi versus Gla-100 on glycemic control measured as TIR…
- Trial name
- China Soli-CGM (NCT06671587)
- Testing
- iGlarLixi (insulin glargine/lixisenatide), Gla-100 (insulin glargine)
- Where
- China
- Volunteers
- 678 people
- Sponsor
- Sanofi
Type 2 Diabetes
A Study of Tirzepatide (LY3298176) Versus Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine With or Without Metformin
The purpose of this study is to compare the safety and efficacy of the study drug tirzepatide to placebo in participants with type 2 diabetes that are already on insulin glargine, with or without metformin.
- Trial name
- SURPASS-5 (NCT04039503)
- Testing
- Tirzepatide
- Where
- 48 sites in United States, Czechia and 6 more
- Volunteers
- 475 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes
Efficacy and Safety of Semaglutide Injection vs Ozempic® in Patients With Type 2 Diabetes
This is a 32-week randomized, open-label, parallel-controlled biosimilar comparison study comparing the efficacy, safety and immunogenicity of the investigational drug and the active comparator in patients with type 2 diabetes…
- Trial name
- NCT06739044
- Testing
- Ozempic®, HDG1901
- Where
- China
- Volunteers
- 494 people
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Overweight and/or Obesity, Weight Management
A Phase Ib/IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Ecnoglutide Tablets in Chinese Participants With Overweight or Obesity
The aim of the study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of oral ecnoglutide tablets in Chinese participants with overweight or obesity
- Trial name
- NCT07243171
- Testing
- ecnoglutide tablets
- Where
- China
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Hangzhou Sciwind Biosciences Co., Ltd.
Obesity, Overweight
A Study of Weekly Oral Dose of Ecnoglutide (VRB-101) for Weight Maintenance in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities
The purpose of this study is to identify the weekly oral dose of VRB-101 (oral ecnoglutide) that can effectively maintain body weight in participants with a history of obesity or overweight with weight-related comorbidities.
- Conditions
- Obesity, Overweight, Weight Maintenance
- Trial name
- NCT07553299
- Testing
- VRB-101
- Where
- 20 sites in United States
- Volunteers
- 8 people
- Sponsor
- Verdiva Bio Dev Limited
Obesity, Weight Management
A Study to Compare XW003 Injection and Semaglutide Injection in Chinese Adults With Obesity (SLIMMER-UP-SWITCH)
The aim of the study is to compare the efficacy and safety of XW003 injection versus semaglutide injection in Chinese adults with obesity
- Trial name
- NCT07073417
- Testing
- XW003 injection, semaglutide injection
- Where
- China
- Volunteers
- 163 people
- Sponsor
- Hangzhou Sciwind Biosciences Co., Ltd.